Spectranetics Achieves Third Quarter Revenue of $35.2 Million

10% Increase Over Q3 2011; 11% Constant Currency Growth Updates 2012 Outlook

        Print
| Source: The Spectranetics Corporation

COLORADO SPRINGS, Colo., Oct. 30, 2012 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) today reported financial results for the three and nine months ended September 30, 2012. Highlights of the quarter (all compared with the quarter ended September 30, 2011) include:

  • Lead Management revenue growth of 18%, 20% on a constant currency basis1
  • Vascular Intervention revenue growth of 6%, 8% on a constant currency basis, led by U.S. peripheral atherectomy growth of 17%
  • U.S. revenue increased 10% to $29.6 million; International revenue increased 6% to $5.6 million, 16% growth on a constant currency basis

"The third quarter of 2012 marks our fourth consecutive quarter of double digit revenue growth on a constant currency basis," said President and Chief Executive Officer, Scott Drake. "We continue to drive strong performance in our focus areas – lead management and peripheral atherectomy. We expect continued growth moving forward, bolstered by our U.S. PAD awareness campaign, opportunities to place our lasers with office-based physicians and the launch of GlideLight™. Based on ongoing strength across all product lines, we are updating our outlook for 2012 to the high end of our previously provided range."

Net income for the third quarter of 2012 was $905,000, or $0.03 per diluted share, compared with net income of $109,000, or $0.00 per diluted share, for the third quarter of 2011. Non-GAAP adjusted net income for the third quarter of 2011 was $935,000, or $0.03 per diluted share, which excluded a special item described under the heading "Reconciliation of Non-GAAP Financial Measures" later in this release.

Year-To-Date Financial Results

Revenue for the nine months ended September 30, 2012 rose 9% (10% on a constant currency basis) to $103.5 million, from $94.8 million in the 2011 period. Vascular Intervention revenue increased 9% (10% on a constant currency basis) to $50.7 million; Lead Management revenue increased 15% (17% on a constant currency basis) to $39.8 million; and laser system, service and other revenue decreased 5% (down 4% on a constant currency basis) to $13.1 million.

On a geographic basis, United States revenue was $86.6 million, an increase of 10% from 2011. International revenue totaled $16.9 million, an increase of 7% (13% on a constant currency basis) from the 2011 period.

Net income during the nine months ended September 30, 2012 was $1.6 million, or $0.04 per diluted share, compared with net income of $539,000 or $0.02 per diluted share, in the nine months ended September 30, 2011. Non-GAAP adjusted net income for the nine months ended September 30, 2011 was $1.4 million, or $0.04 per diluted share,which excluded a special item described under the heading "Reconciliation of Non-GAAP Financial Measures" later in this release.

2012 Outlook

Management projects that 2012 revenue will be in the range of $138.5 - $139.5 million, an increase of 9% - 10% from 2011, or 10% - 11% on a constant currency basis. This compares to the previous outlook for revenue in the range of $137.0 - $139.5 million.

Net income is projected to be in the range of $2.0 - $3.0 million, or $0.06 - $0.08 per diluted share. This compares to the previous outlook for net income in the range of $1.5 - $3.0 million, or $0.04 - $0.08 per diluted share. Management expects to continue making investments targeted at future revenue growth.

Conference Call

Management will host an investment community conference call today beginning at 9:00 a.m. Mountain time, 11:00 a.m. Eastern time, to discuss these results and answer questions. Individuals interested in listening to the conference call may do so by dialing (877) 561-2747 for domestic callers, or (973) 409-9689 for international callers, or from the webcast on the investor relations section of the Company's Web site at: www.spectranetics.com. The webcast will be available on the Company's Web site for 14 days following the completion of the call.

About Spectranetics

Spectranetics develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are sold in more than 40 countries and are used to treat arterial blockages in the heart and legs, as well as the removal of pacemaker and defibrillator leads.

The Company's Vascular Intervention (VI) products include a range of peripheral and cardiac laser catheters for ablation of occluded arteries above and below the knee and within coronary arteries. The Company also markets aspiration and thrombectomy catheters for the removal of thrombus and support catheters to facilitate crossing of coronary and peripheral arterial blockages.

The Lead Management (LM) product line includes excimer laser sheaths and cardiac lead management accessories for the removal of pacemaker and defibrillator cardiac leads.

For more information, visit www.spectranetics.com.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding our expectation of continued growth and the reasons for that growth, growth rates, and 2012 outlook including projected revenue and net income. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties may include greater than anticipated indemnification obligations or other adverse results in connection with any ongoing legal proceeding, or any legal proceeding in which we may become involved, adverse impact to our business of the healthcare reform and related legislation, continued or worsening adverse conditions in the general domestic and global economic markets and continued volatility and disruption of the credit markets, which, among other things, affects the ability of hospitals and other health care systems to obtain credit and may impede our access to capital, market acceptance of excimer laser atherectomy technology and our lead removal products, increasing price and product competition, increased pressure on expense levels resulting from expanded sales, marketing, product development and clinical activities, uncertain success of our strategic direction, dependence on new product development, intellectual property claims of third parties, availability of inventory from suppliers, adverse outcome of FDA inspections, the receipt of FDA approval to market new products or applications and the timeliness of any approvals, market acceptance of new products or applications, product defects, ability to manufacture sufficient volumes to fulfill customer demand, availability of vendor-sourced components at reasonable prices, unexpected delays or costs associated with any planned improvements to our manufacturing processes, and share price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. For a further list and description of such risks and uncertainties that could cause our actual results, performance or achievements to be materially different from any anticipated results, performance or achievements, please see our previously filed SEC reports, including those risks set forth in our 2011 Annual Report on Form 10-K. We disclaim any intention or obligation to update or revise any financial or other projections or other forward-looking statements, whether as a result of new information, future events or otherwise.

Use of Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures in this release. Reconciliations of the non-GAAP financial measures used in this release to the most directly comparable U.S. GAAP measures for the respective periods, and an explanation of our use of these non-GAAP measures, can be found in "Reconciliation of Non-GAAP Financial Measures" immediately following the financial tables. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP.

   
1Constant currency is a non-GAAP financial measure. See "Reconciliation of Non-GAAP Financial Measures" later in this release.
 
 
THE SPECTRANETICS CORPORATION
Condensed Consolidated Statements of Operations
(000's, except per share data and percentages)
(unaudited)
 
  Three Months Ended
September 30,
Nine Months Ended
September 30,
  2012 2011 2012 2011
Revenue $35,230 $32,127 $103,534 $94,763
Cost of products sold 9,624 8,683 28,112 26,923
Gross profit 25,606 23,444 75,422 67,840
Gross margin % 73% 73% 73% 72%
Operating expenses:        
Selling, general and administrative 20,324 17,716 61,287 52,707
Research, development and other technology 4,181 4,729 12,134 13,663
Litigation charge 596 596
Total operating expenses 24,505 23,041 73,421 66,966
Operating income 1,101 403 2,001 874
Litigation-related interest expense (230) (230)
Other income, net 46 16 11 133
Total other income (expense) 46 (214) 11 (97)
Income before taxes 1,147 189 2,012 777
Income tax expense 242 80 459 238
Net income $905 $109 $1,553 $539
         
Net income per common share:        
Basic $0.03 $0.00 $0.05 $0.02
Diluted 0.03 0.00 0.04 0.02
Weighted average shares outstanding:  
Basic 34,549 33,546 34,268 33,370
Diluted 35,945 34,391 35,551 34,271
         
 
THE SPECTRANETICS CORPORATION
Condensed Consolidated Balance Sheets
(000's)
 
  9/30/2012 12/31/2011
  (unaudited)  
ASSETS    
Current assets:    
Cash and cash equivalents $31,646 $39,638
Accounts receivable, net 19,994 18,123
Inventories, net 9,879 8,542
Deferred income taxes, current portion, net 457 610
Other current assets 2,167 2,421
Total current assets 64,143 69,334
Property and equipment, net 26,731 27,249
Goodwill 13,296 11,569
Other assets 649 884
Total assets $104,819 $109,036
     
LIABILITIES AND STOCKHOLDERS' EQUITY    
Current liabilities $17,131 $27,960
Non-current liabilities 1,775 1,566
Stockholders' equity 85,913 79,510
Total liabilities and stockholders' equity $104,819 $109,036
 
 
THE SPECTRANETICS CORPORATION
Supplemental Financial Information
(Unaudited)
           
 Financial Summary 2011  2012
(000's, except laser sales and installed base amounts) 3rd Qtr 4th Qtr 1st Qtr 2nd Qtr 3rd Qtr
         
Disposable products revenue:          
Vascular Intervention revenue $15,860 $15,877 $16,411 $17,420 $16,821
Lead Management revenue 11,800 11,893 12,368 13,526 13,918
Total disposable products revenue 27,660 27,770 28,779 30,946 30,739
           
Service and other revenue 2,517 2,541 2,659 2,515   2,508
         
Laser revenue:          
Equipment sales 719 909 591 409 910
Rental fees 1,231 1,304 1,240 1,165 1,073
Total laser revenue 1,950 2,213 1,831 1,574 1,983
           
Total revenue 32,127 32,524 33,269 35,035 35,230
           
Net income 109 355 12 636 905
Non-GAAP adjusted net income excluding special items (1) 935 1,310 N/A N/A N/A
           
Cash flow generated by (used in) operating activities 338 3,051 (4,713) 423 3,748
Total cash and current investment securities at end of quarter 36,154 39,638 27,000 27,659 31,646
           
Laser sales summary:          
Laser sales from inventory 4 5 3 2 5
Laser sales from evaluation/rental units 3 3 1 1
Total laser sales 7 8 3 3 6
           
(1) Non-GAAP adjusted net income excluding special items is a non-GAAP financial measure. Please refer to the non-GAAP reconciliation tables following this table for the reconciliation of the third and fourth quarters of 2011. There were no special items reported in the first, second or third quarters of 2012.
         
Worldwide Installed Base Summary:        
Laser sales from inventory 4 5 3 2 5
Rental placements 19 21 15 18 21
Evaluation placements 6 4 7 8 4
Laser placements during quarter 29 30 25 28 30
Buy-backs/returns during quarter (10) (13) (13) (14) (19)
Net laser placements during quarter 19 17 12 14 11
Total lasers placed at end of quarter 994 1,011 1,023 1,037 1,048

Reconciliation of Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements prepared in accordance with GAAP, we use certain non-GAAP financial measures in this release. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures for the respective periods can be found in the tables below. An explanation of the manner in which our management uses these non-GAAP measures to conduct and evaluate our business and the reasons why management believes that these non-GAAP measures provide useful information to investors is provided following the reconciliation tables.  

THE SPECTRANETICS CORPORATION
Reconciliation of revenue by geography to non-GAAP revenue by geography
on a constant currency basis
(000's, except percentages)
(unaudited)
 
  Three Months Ended  
 
September 30, 2012
September 30,
2011

Change
 



Revenue,
as reported
Foreign
exchange
impact as
compared
to prior
period


Revenue on
a constant
currency
basis




Revenue, as
reported





As reported



Constant
currency
basis
United States $29,625 $— $29,625 $26,836 10% 10%
International 5,605 546 6,151 5,291 6% 16%
Total revenue $35,230 $546 $35,776 $32,127 10% 11%
   
  Nine Months Ended  
 
September 30, 2012
September 30,
2011

Change
 


Revenue, as
reported
Foreign
exchange
impact as
compared
to prior
period

Revenue on
a constant
currency
basis



Revenue, as
reported




As reported


Constant
currency
basis
United States $86,617 $— $86,617 $78,883 10% 10%
International 16,917 1,068 17,985 15,880 7% 13%
Total revenue $103,534 $1,068 $104,602 $94,763 9% 10%
 
 
THE SPECTRANETICS CORPORATION
Reconciliation of revenue by product line to non-GAAP revenue by product line
on a constant currency basis
(000's, except percentages)
(unaudited)
 
  Three Months Ended  
 
September 30, 2012
September 30,
2011

Change
 



Revenue,
as reported
Foreign
exchange
impact as
compared
to prior
period


Revenue on
a constant
currency
basis




Revenue, as
reported




As reported




Constant
currency
basis
Vascular Intervention $16,821 $232 $17,053 $15,860 6% 8%
Lead Management 13,918 264 14,182 11,800 18% 20%
Laser System, Service & Other 4,491 50 4,541 4,467 1% 2%
Total revenue $35,230 $546 $35,776 $32,127 10% 11%
     
  Nine Months Ended  
 
September 30, 2012
September 30,
2011

Change
 



Revenue,
as reported
Foreign
exchange
impact as
compared
to prior
period


Revenue on
a constant
currency
basis
 



Revenue, as
reported

 



As reported




Constant
currency
basis
Vascular Intervention $50,652 $425 $51,077 $46,387 9% 10%
Lead Management 39,812 509 40,321 34,587 15% 17%
Laser System, Service & Other 13,070 134 13,204 13,789 (5)% (4)%
Total revenue $103,534 $1,068 $104,602 $94,763 9% 10%
 
 
THE SPECTRANETICS CORPORATION
Reconciliation of Net Income to Non-GAAP Adjusted Net Income Excluding Special Items and
Net Income per Diluted Share to Non-GAAP Adjusted Net Income Excluding Special Items 
per Diluted Share
(000's, except per share data)
(unaudited)
           
  Three Months Ended September 30, Nine Months Ended September 30,
  2012 2011 2012 2011
  Net income Per diluted
share (1)
Net income Per diluted
share (1)
Net income Per diluted
share (1)
Net income Per diluted
share (1)
Net income, as reported  $905 $0.03 $109 $0.00 $1,553 $0.04 $539 $0.02
Litigation charge (2)   —  596 0.02 596 0.02
Litigation-related interest expense (2)  230 0.01 230 0.01
Non-GAAP adjusted net income excluding special items  $905 $0.03 $935 $0.03 $1,553 $0.04 $1,365 $0.04
   
  Three Months Ended
December 31, 2011
 
Net income
Per diluted
share (1)
Net income, as reported  $355 $0.01
Federal investigation legal and accrued indemnification costs (3)  (370) (0.01)
Settlement costs -- license agreement dispute (4)  1,821 0.05
Decrease in valuation allowance against deferred tax asset (5)  (496) (0.01)
Non-GAAP adjusted net income excluding special items  $1,310 $0.04
 
1)  Per share amounts may not add due to rounding. Per diluted share is calculated based on the fully diluted weighted average shares outstanding for all periods. The fully diluted weighted average shares were 35,945,453 and 35,550,565 for the three and nine months ended September 30, 2012, respectively, 34,390,829 and 34,271,029 for the three and nine months ended September 30, 2011, respectively, and 34,631,377 for the three months ended December 31, 2011.
 
2)  In the third quarter of 2011, the Dutch Court of Appeal issued a ruling in favor of Cardiomedica S.p.A., requiring us to pay $0.6 million plus $0.2 million of interest to Cardiomedica. Further information regarding this matter is included in our Annual Report on Form 10-K for the year ended December 31, 2011.
 
3)  In the third quarter of 2010, we accrued a $6.5 million charge to record our estimated liability related to indemnification obligations that we had with three former employees. In the fourth quarter of 2011, we reversed $0.4 million of the original accrual based on developments in the court proceedings, including the conclusion of the trial of two of the defendants and the dismissal of charges against a third defendant. Further information regarding this matter is included in our Annual Report on Form 10-K for the year ended December 31, 2011.
 
4)  In January 2012, we entered into a Termination and Mutual Release ("Agreement") with Medtronic, Inc. The Agreement terminated the License Agreement between us and Medtronic dated February 28, 1997. Under the Agreement, we paid Medtronic $3.0 million in January 2012. We had accrued royalty expenses in the amount of $1.2 million prior to the settlement; therefore, the amount of $1.8 million was recorded as settlement costs—license agreement dispute. The Agreement includes a mutual release and no further royalty expenses will be incurred subsequent to the effective date of the Agreement. 
 
5)  In the fourth quarter of 2011, we entered into a strategic tax transaction with the approval of the Dutch tax authority that effectively extended the life of a portion of a net operating loss (NOL) carryforward in the Netherlands, which had previously been scheduled to expire on December 31, 2011 and which had previously been fully reserved. As a result, we recorded a $0.5 million tax benefit representing our estimate of the actual utilization of the extended deduction in future years.

Management uses the non-GAAP financial measures as supplemental measures to analyze the underlying trends in our business, assess the performance of our core operations, establish operational goals and forecasts that are used in allocating resources and evaluate our performance period over period and in relation to our competitors' operating results.

The impact of foreign exchange rates is highly variable and difficult to predict. We use a constant currency basis to show the impact from foreign exchange rates on current period revenue compared to prior period revenue using the prior period's foreign exchange rates. In order to properly understand the underlying business trends and performance of our ongoing operations, we believe that investors may find it useful to consider the impact of excluding changes in foreign exchange rates from our revenue.

We believe that presenting the non-GAAP financial measures used in this release provides investors greater transparency to the information used by our management for financial and operational decision-making and allows investors to see our results "through the eyes" of management. We also believe that providing this information better enables our investors to understand our operating performance and evaluate the methodology used by management to evaluate and measure such performance.

Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP. Some of the limitations associated with our use of these non-GAAP financial measures are provided below:

  • Management exercises judgment in determining which types of charges or other items should be excluded from the non-GAAP financial measures used.
     
  • Items such as the federal investigation legal and accrued indemnification costs, the license agreement termination charge and the litigation charge and related interest that are excluded from net income and net income per share can have a material impact on cash flows, GAAP net income and net income per share and reflect economic costs to us that are not reflected in non-GAAP adjusted net income and non-GAAP adjusted net income per share.
     
  • The decrease in the valuation allowance against the deferred tax assets represents a change in the value of assets. The benefit associated with this change in value is not included in our non-GAAP adjusted net income or non-GAAP adjusted net income per share.
     
  • Revenue growth rates stated on a constant currency basis, by their nature, exclude the impact of foreign exchange, which may have a material impact on GAAP revenue.
     
  • Non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles and therefore other companies may calculate similarly titled non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.
COMPANY CONTACT
The Spectranetics Corporation
Guy Childs, Chief Financial Officer
(719) 633-8333

INVESTOR CONTACTS
Westwicke Partners
Lynn Pieper or Nicole Hellendoorn
(415) 202-5678